DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy

Study summary

The hypotheses of the study are as follows: * Mass-based inverse optimization in radiotherapy treatment planning will result in a reduction of normal tissue and organs at risk (OAR) doses for desired prescription therapeutic doses to the targets. * Dose-mass histograms (DMHs) may be more relevant to radiotherapy treatment planning and treatment plan assessment than the standard of care, realized through dose-volume histograms (DVHs)

Ask AI to explain this study

Start here

Key things to know

Main goalHealth Services Research

This describes the study’s primary purpose.

What is being studiedCT Scan

The study team can explain what participation involves.

Who it may be forHead and Neck Cancer · Lung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 5, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?University of Miami

Study sponsor

Study overview

What this study is about

Purpose: Health Services Research
Study type: Interventional
Phase: Not applicable
Sponsor: University of Miami
Interventions being studied: Device: CT Scan

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Radiation therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Patients must have histologically confirmed head-and-neck, lung, or prostate tumors.
Patients who will be treated with radiation therapy or concurrent chemoradiation therapy.
Gross Tumor Volume (GTV) or resection cavity must be visible on CT such that it can be delineated as a target for radiotherapy.
Patients who are able to understand the investigational nature of this study and agree to sign a written informed consent document.

Reasons someone may not be able to joinExclusion criteria

Pregnant or nursing women will not participate. Women of reproductive potential must be offered a pre-treatment pregnancy test and informed of the need to practice an effective contraceptive method during the therapy.
Patients younger than 18 years.
Patients whose size and weight would not allow CT scanning.
No vulnerable populations (fetuses, pregnant women, children, prisoners) will be included in this study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of MiamiMiami, Florida

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 5, 2020. Always confirm current availability with the study team.

View original record ↗